Methicillin-resistant Staphylococcus aureus (MRSA) is a common infectious pathogen during stem cell transplantation. We report a case of meningoencephalitis with multiple abscess formation caused by MRSA, which occurred in a 4-year-old boy soon after allogeneic peripheral blood stem cell transplantation. We successfully cured the infection with a combination of intravenous and intrathecal vancomycin.
Infectious complications caused by methicillin-resistant Staphylococcus aureus (MRSA) are a serious problem in patients who receive intensive chemotherapy with or without stem cell transplantation. Although vancomycin is the most promising agent for the management of such infections, it is often difficult to achieve an effective therapeutic level in cerebrospinal fluid (CSF) by intravenous (i.v.) infusion because of poor penetration of vancomycin through the blood-brain barrier. Direct instillation of vancomycin into the CSF is a possible alternative to achieve adequate CSF concentrations and eventual success in controlling this infection. Several investigators have reported the successful use of intraventricular vancomycin to shunt-related ventriculitis or meningitis mainly caused by coagulase-negative Staphylococci.
1,2 However, there has been no report on the use of this procedure with MRSA meningoencephalitis in an immunosuppressed patient. We report a 4-year-old boy who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). The post-transplant course was complicated by MRSA meningoencephalitis, which was successfully treated with a protracted course of intrathecal vancomycin.
Case report
A 4-year-old boy was hospitalized in August 2000 because of newly diagnosed acute myeloid leukemia (AML). He had previously had bilateral retinoblastoma, which developed at the age of 13 months. For this, he received external beam radiotherapy (40 Gy) to both eyes, followed by systemic chemotherapy. The interval between the onset of AML and the end of his last chemotherapy was 2 years. He achieved complete remission after one course of induction chemotherapy, and continued to receive intensification chemotherapy until February 2001, when he underwent allogeneic PBSCT from an HLA onelocus-mismatched uncle. The conditioning regimen consisted of busulfan (140 mg/m 2 Â 4) and cyclophosphamide (60 mg/kg Â 2), followed by the infusion of unmanipulated allogeneic PBSC that contained 5.7 Â 10 6 /kg CD34+ cells. Cyclosporin A (3 mg/kg) and a short course of methotrexate (10 mg/m 2 on day 1, and 7 mg/m 2 on days 3 and 6) were given as graft-versus-host disease prophylaxis. Although the patient had a history of MRSA infection 6 months prior to transplantation, follow-up cultures for MRSA were all negative. Therefore, he did not receive prophylactic antibacterial treatment for MRSA up-front. Only intravenous acyclovir and oral amphotericin B were used. On day 6 of the transplant, he developed chills and a high temperature of up to 401C. Empiric antibiotic therapy with i.v. piperacillin 100 mg/kg/day divided into three doses and i.v. aztreonam 100 mg/kg/day divided into three doses was started. The next day, these were replaced with a combination of i.v. panipenem/betamipron and i.v. vancomycin (VCM), based on the isolation of Grampositive cocci from the blood and stool. These strains were later proven to be MRSA. Despite neutrophil engraftment (40.5 Â 10 9 /l) on post-transplant day 12, high fever continued and he gradually became drowsy and agitated. Computed tomography (CT) scan of the brain did not show any signs of inflammatory disease on day 12, while lumbar puncture performed on the same day revealed that the CSF contained 454 cells/mm 3 consisting of 84% mononuclear cells and 16% neutrophils. The CSF showed protein 77 mg/dl, glucose 69 mg/dl and LDH 145 IU/l, and CSF culture was positive for MRSA, which had the same drug-sensitivity pattern as that of the strain isolated from the blood. A magnetic resonance imaging (MRI) scan of the brain taken on day 17 revealed multiple small nodules in the white matter of the brain, and a diagnosis of meningoencephalitis with abscess formation was confirmed. The minimal inhibitory concentrations (MIC) of VCM and arbekacin (ABK) for the MRSA strains isolated were 2 and 3.13 mg/ml, respectively. From day 18, after obtaining consent from his parents, i.v. ABK 100 mg/kg/day and intrathecal (i.t.) 5 mg VCM were started. The next day, the CSF concentrations of VCM and ABK were 4.7 and 1.1 mg/ml, respectively. In an attempt to raise the CSF level of ABK to above the MIC, we gave three doses of i.t. ABK 5 mg while i.t. VCM was withheld for the following 3 days. Although his consciousness level and general condition improved, the high fever and leukocytosis in the CSF continued. Therefore, on day 22 we restarted i.t. VCM and administered ABK intravenously. CSF culture for MRSA became negative after day 17. MRI showed multiple ring-enhancing small lesions in the whole brain on FLAIR (Figure 1 ) when evaluated on day 25. His mental status had completely normalized by day 27. CSF leukocytosis resolved around day 40 and his fever lessened. The multiple small nodules had disappeared on MRI examination on day 40. Levels of VCM in the CSF were carefully monitored (2.9-9.9 mg/ml) to maintain a therapeutic level. Intrathecal VCM was given biweekly until day 43 to a total of 10 doses, with a cumulative dose of 50 mg. VCM was then administered i.v. until day 63.
No adverse events directly related to the i.t. VCM or ABK were noted. MRSA infection did not recur up to day 185, when he died of bronchiolitis obliterans secondary to allogeneic PBSCT, without evidence of GVHD. Autopsy was not performed.
Discussion
To the best of our knowledge, there have been no previous reports of successfully treated MRSA meningitis or encephalitis developing after stem cell transplantation. In our case, the prompt use of i.v. VCM failed to control the MRSA infection and, consequently, brain abscesses developed. Based on the data reported by Redfield et al 3 i.v. VCM may not achieve adequate CSF levels to treat central nervous system (CNS) infection, especially when there is no meningitis. Therefore, i.t. VCM was given in an effort to maintain an adequate therapeutic level of VCM in the CSF.
Several investigators have conducted pharmacokinetic studies after the i.t. VCM. [1] [2] [3] [4] Bayston et al 1 successfully treated 18 of 33 patients with ventriculitis who failed to respond to i.v. VCM with intraventricular VCM. Based on their data, they recommended a dose of 10-20 mg of intraventricular VCM every 24 h in adults. Reesor et al 2 measured CSF levels once or twice daily in patients receiving intraventricular VCM therapy. They recommended initial treatment with 8-10 mg to achieve a peak CSF concentration of 30-50 mg/ml. Based on these data, we decided to use a dose of 5 mg i.t. VCM. During the biweekly i.t. injections, trough levels of VCM in the CSF ranged between 2.9 and 9.8 mg/ml. Since the MIC of VCM for the MRSA strains isolated in this patient was 2.0 mg/ml, a dose of 5 mg i.t. VCM was considered to be adequate to manage the CNS infection.
Although several reports have indicated possible side effects associated with i.t. VCM, including changes in the mental status 5 and severe headache, 6 our patient had no evidence of neurological problems secondary to VCM. Since the severity of the side effects appears to be related to the peak VCM level in the CSF, 5, 7, 8 we suggest that careful monitoring of the CSF VCM level could prevent excessive adverse events.
We noted failure of response to i.t. ABK with MRSA meningoencephalitis. A possible explanation would be the fact that the antibacterial activity of aminoglycosides is pHdependent, with increased activity at higher pH, and it has been shown that in cases of meningitis the CSF becomes acidic. 9 The emergence of glycopeptide-resistant coagulase-negative staphylococci in patients treated for long periods with VCM and teicoplanin has been increasingly documented. 10 In vitro, linezolid, quinupristin-dalfopristin, moxifloxacin and trovafloxacin, which are new antibiotics, reveal good activity against MRSA and methicillin-resistant and teicoplaninintermediate coagulase negative staphylococci.
11 In particular, linezolid has an acceptable safety profile for both i.v. and oral administration and has proven effective in the treatment of infections caused by methicillin-resistant staphylococcal species in critically ill patients. 12 Intravenous linezolid also appears to be a safe and effective therapy for vancomycin-resistant enterococcus meningitis [13] [14] [15] and linezolid achieved sufficient CSF concentrations to bring about clinical and bacteriological cure. 16, 17 Based on our experience and the data reported to date, i.t. VCM might be a safe and effective second-line treatment for Staphylococcal CNS infections in immunocompromised patients. For rational use of i.t. VCM, with MRSA meningoencephalitis in Allo-PBSCT recipient H Matsubara et al maximum efficacy and minimum toxicity, we recommend that CSF drug levels should be closely monitored and the dose should be adjusted to reasonably exceed the MIC of the target bacterial strain.
